Titan Net Invested Capital vs Total Liab Analysis
| TTNP Stock | USD 6.48 0.07 1.07% |
Titan Pharmaceuticals financial indicator trend analysis is much more than just breaking down Titan Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Titan Pharmaceuticals is a good investment. Please check the relationship between Titan Pharmaceuticals Net Invested Capital and its Total Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.
Net Invested Capital vs Total Liab
Net Invested Capital vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Titan Pharmaceuticals Net Invested Capital account and Total Liab. At this time, the significance of the direction appears to have very week relationship.
The correlation between Titan Pharmaceuticals' Net Invested Capital and Total Liab is 0.28. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Total Liab in the same time period over historical financial statements of Titan Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Titan Pharmaceuticals' Net Invested Capital and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Titan Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Net Invested Capital i.e., Titan Pharmaceuticals' Net Invested Capital and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.28 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Titan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Titan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.At this time, Titan Pharmaceuticals' Sales General And Administrative To Revenue is relatively stable compared to the past year. As of 05/16/2024, Enterprise Value Over EBITDA is likely to grow to 0.0006, while Issuance Of Capital Stock is likely to drop slightly above 7.2 M.
Titan Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Titan Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Titan Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 9.5M | 8.1M | 8.0M | 4.1M | 8.1M | 7.7M | |
| Short Long Term Debt Total | 4.4M | 809K | 299K | 187K | 565K | 536.8K | |
| Other Current Liab | 1.9M | 2.0M | 1.5M | 1.6M | 519K | 493.1K | |
| Total Current Liabilities | 3.6M | 4.2M | 2.7M | 2.6M | 1.4M | 1.4M | |
| Total Stockholder Equity | 1.4M | 3.5M | 5.1M | 1.4M | 6.6M | 6.3M | |
| Property Plant And Equipment Net | 1.2M | 759K | 717K | 407K | 68K | 64.6K | |
| Net Debt | (782K) | (4.6M) | (5.7M) | (2.8M) | (6.2M) | (6.5M) | |
| Retained Earnings | (349.0M) | (367.3M) | (376.1M) | (386.3M) | (391.8M) | (372.2M) | |
| Accounts Payable | 1.4M | 1.3M | 795K | 695K | 348K | 330.6K | |
| Cash | 5.2M | 5.4M | 6.0M | 2.9M | 6.8M | 8.3M | |
| Non Current Assets Total | 1.2M | 759K | 765K | 455K | 68.0K | 64.6K | |
| Non Currrent Assets Other | 794K | (1.2M) | (759K) | 48K | (1.0) | (0.95) | |
| Cash And Short Term Investments | 5.2M | 5.4M | 6.0M | 2.9M | 6.8M | 6.4M | |
| Net Receivables | 993K | 884K | 112K | 36K | 1.0M | 1.6M | |
| Common Stock Shares Outstanding | 1.3K | 188.7K | 486.5K | 671.7K | 752K | 789.6K | |
| Liabilities And Stockholders Equity | 9.5M | 8.1M | 8.0M | 4.1M | 8.1M | 7.7M | |
| Non Current Liabilities Total | 3.8M | 4.5M | 332K | 187K | 65K | 0.0 | |
| Other Stockholder Equity | 350.4M | 370.8M | 381.2M | 387.6M | 398.5M | 418.4M | |
| Total Liab | 8.1M | 4.6M | 2.9M | 2.7M | 1.4M | 1.4M | |
| Total Current Assets | 8.3M | 7.3M | 7.2M | 3.6M | 8.0M | 7.6M | |
| Short Term Debt | 272K | 477K | 112K | 122K | 565K | 1.1M | |
| Other Current Assets | 1.1M | 522K | 480K | 314K | 199K | 189.1K | |
| Property Plant And Equipment Gross | 1.2M | 618K | 2.1M | 2M | 774K | 883.3K | |
| Common Stock | 57K | 7K | 10K | 15K | 1K | 950.0 | |
| Property Plant Equipment | 794K | 1.2M | 759K | 717K | 824.6K | 826.4K | |
| Long Term Debt | 3.6M | 3.8M | 4.0M | 332K | 298.8K | 283.9K | |
| Retained Earnings Total Equity | (323.3M) | (332.6M) | (349.0M) | (367.3M) | (330.6M) | (347.1M) | |
| Net Tangible Assets | 6.8M | 1.4M | 3.5M | 5.1M | 4.6M | 4.7M | |
| Capital Surpluse | 26.3M | 339.4M | 350.4M | 370.8M | 426.4M | 447.7M | |
| Net Invested Capital | 5.5M | 4.2M | 5.1M | 1.4M | 7.1M | 4.8M |
Currently Active Assets on Macroaxis
When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Titan Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Titan Stock analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.41) | Revenue Per Share 0.245 | Quarterly Revenue Growth (1.00) | Return On Assets (0.75) | Return On Equity (1.39) |
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.